• June 3-6, 2024
  • San Diego Convention Center, California

Sessions

Loading

Exploring the Uncharted: Rare Diseases, Unintended Consequences of the Inflation Reduction Act, and Demonstrating the Value of These Therapies

Tuesday, June 04, 2024
Breakout Session
Orphan and Rare Disease
30DE
President Biden signed the Inflation Reduction Act into law on August 16, 2022. Almost two years later, our panel will evaluate how the law has impacted rare disease research and development. Our expert panel will provide insights into how the Act's provisions could influence treatment affordability and availability for rare disease patients. Our panel will also touch on how to demonstrate the value of rare disease therapies in the space. This session is designed to spark a constructive dialogue among advocates, policymakers, and other stakeholders.
Moderator
Michele Oshman
Senior Vice President and Head of Patient Advocacy
Biotechnology Innovation Organization (BIO)
Speakers
Jason Spangler, MD, MPH, FACPM
Chief Executive Officer
Innovation and Value Initiative’s (IVI)
Karin Hoelzer, DVM, PhD
Senior Director, Policy and Regulatory Affairs
National Organization for Rare Disorders (NORD)
Dionne Stalling
Executive Director
Rare And Black
Kate Jones
Head of Federal Affairs
Alexion, AstraZeneca Rare Disease

Sponsored by:

alexion logo
Back to Session List

white squarewhite

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS